Login to Your Account

Oxford BioTherapeutics, GSK Form $370M Cancer Alliance

By Cormac Sheridan

Wednesday, May 20, 2009
Oxford BioTherapeutics (OBT) Ltd. entered its first big pharma drug discovery and development deal, a potential $370 million pact with GlaxoSmithKline plc to develop antibody therapies against cancer. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription